MacroGenics (MGNX)
(Delayed Data from NSDQ)
$16.07 USD
-0.03 (-0.19%)
Updated Apr 18, 2024 04:00 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for MacroGenics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 59 | 152 | 77 | 105 | 64 |
Cost Of Goods | 8 | 7 | 3 | 0 | 0 |
Gross Profit | 51 | 145 | 75 | 105 | 64 |
Selling & Adminstrative & Depr. & Amort Expenses | 219 | 266 | 278 | 236 | 241 |
Income After Depreciation & Amortization | -168 | -121 | -203 | -131 | -177 |
Non-Operating Income | 161 | 2 | 1 | 1 | 25 |
Interest Expense | 1 | 0 | 0 | 0 | 0 |
Pretax Income | -9 | -120 | -202 | -130 | -152 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -120 | -202 | -130 | -152 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -120 | -202 | -130 | -152 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -164 | -109 | -190 | -119 | -166 |
Depreciation & Amortization (Cash Flow) | 5 | 12 | 13 | 12 | 11 |
Income After Depreciation & Amortization | -168 | -121 | -203 | -131 | -177 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.93 | 61.43 | 59.95 | 52.44 | 48.08 |
Diluted EPS Before Non-Recurring Items | -2.08 | -1.95 | -3.37 | -2.47 | -3.16 |
Diluted Net EPS (GAAP) | -0.15 | -1.95 | -3.37 | -2.47 | -3.16 |
Fiscal Year end for MacroGenics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 10.72 | 10.40 | 13.14 | 24.50 |
Cost Of Goods | NA | 0.16 | 3.36 | 1.18 | 3.52 |
Gross Profit | NA | 10.56 | 7.04 | 11.96 | 20.97 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 59.91 | 42.54 | 56.92 | 59.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -49.35 | -35.50 | -44.96 | -38.43 |
Non-Operating Income | NA | 3.28 | 53.06 | 103.21 | 1.07 |
Interest Expense | NA | 0.00 | 0.00 | 0.77 | 0.66 |
Pretax Income | NA | -46.07 | 17.55 | 57.47 | -38.01 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -46.07 | 17.55 | 57.47 | -38.01 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -46.07 | 17.55 | 57.47 | -38.01 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.43 | 62.25 | 62.26 | 61.81 |
Diluted EPS Before Non-Recurring Items | NA | -0.75 | -0.52 | -0.36 | -0.61 |
Diluted Net EPS (GAAP) | NA | -0.74 | 0.28 | 0.92 | -0.61 |